Company Starpharma Holdings Limited

SPL

AU000000SPL0

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Annual profits - Rate of surprise

Sector Other Pharmaceuticals

Delayed Australian S.E. Other stock markets 10:01:48 2024-04-18 pm EDT			5-day change	1st Jan Change
0.13 ^AUD	+4.00%		-3.70%	-23.53%

Apr. 08	Starpharma, Medicxi Co-Found Petalion Therapeutics; Shares Surge 16%	MT
Mar. 18	Starpharma Holdings Limited(ASX:SPL) dropped from S&P/ASX Emerging Companies Index	CI

Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. It is focused on developing and commercializing novel therapeutic products that address global healthcare needs. The Company is also involved in the development of nano-scale materials, including the development of VivaGel for the management and prevention of bacterial vaginosis, and as an antiviral condom coating, and VIRALEZE, an antiviral nasal spray. The Company is also applying its proprietary dendrimers to drug delivery to create improved pharmaceuticals and has developed the valuable DEP delivery platform. VIRALEZE is a broad-spectrum nasal spray intended to provide a moisturizing and protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products.

AUD in Million	2022	Weight	2023	Weight	Delta
Dendrimers 100.0 %	5	100.0 %	3	100.0 %	-37.23%

AUD in Million	2022	Weight	2023	Weight	Delta
Australia 100.0 %	5	100.0 %	3	100.0 %	-37.23%

Managers	Title	Age	Since
Cheryl Maley CEO	Chief Executive Officer	-	Jan. 07
Justin Cahill DFI	Director of Finance/CFO	-	23-04-02
Tony Eglezos PRN	Corporate Officer/Principal	-	13-08-11
Jeremy R. Paull LAW	General Counsel	-	00-12-31

Members of the board	Title	Age	Since
Jeff Davies BRD	Director/Board Member	-	22-03-31
Robert Thomas CHM	Chairman	79	13-12-03
David McIntyre BRD	Director/Board Member	53	20-02-29
Russell Basser BRD	Director/Board Member	-	23-02-19
Lynda Cheng BRD	Director/Board Member	-	21-07-31
Cheryl Maley CEO	Chief Executive Officer	-	Jan. 07

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	411,797,758	381,746,364 ( 92.70 %)	0	92.70 %

Name	Equities	%	Valuation
Allianz Global Investors Asia Pacific Ltd. 11.77 %	48,480,000	11.77 %	4 M $
Allan Gray Australia Pty Ltd. 11.61 %	47,820,976	11.61 %	4 M $
ICM Investment Management Ltd. 5.184 %	21,361,682	5.184 %	2 M $
FIL Investment Advisors (UK) Ltd. 4.925 %	20,291,445	4.925 %	2 M $
M&G Investment Management Ltd. 4.407 %	18,156,714	4.407 %	1 M $
Mirrabooka Investments Ltd. (Investment Management) 2.111 %	8,700,063	2.111 %	709 490 $
T&N Argyrides Investments Pty Ltd. 1.228 %	5,060,000	1.228 %	412 643 $
Jacinth Fairley 0.9842 %	4,055,434	0.9842 %	330 721 $
Kingsley Bryan Bartholomew 0.8317 %	3,427,025	0.8317 %	279 474 $
Applecross Secretarial Services Pty Ltd. 0.8158 %	3,361,550	0.8158 %	274 134 $

Starpharma Holdings Ltd.

4-6 Southampton Crescent

3067, Abbotsford

+61 3 8532 2700

http://www.starpharma.com

address Starpharma Holdings Limited(SPL)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
STARPHARMA HOLDINGS LIMITED	-23.53%	34.39M
ELI LILLY AND COMPANY	+27.97%	676B
NOVO NORDISK A/S	+23.58%	554B
JOHNSON & JOHNSON	-7.02%	349B
MERCK & CO., INC.	+14.85%	318B
ABBVIE INC.	+6.25%	291B
ASTRAZENECA PLC	+2.96%	210B
NOVARTIS AG	-0.41%	204B
ROCHE HOLDING AG	-10.02%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals